Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0097 • ACR Convergence 2024
The Human Lupus TREX1 D18N Mutation Engineered in C. Elegans Leads to Cell Death. What Can We Learn About Lupus Using C. Elegans?
Htay Htay Kyi¹, Patricia Barreto², Yeshaswi Pulijala³, Thejasvi Venkatachalam³ and Martha Soto², ¹Rutgers New Jersey Medical School, Jersey City, NJ, ²Robert Wood Johnson Medical School, Piscataway, NJ, ³RWJ-PATHOLOGY-RESEARCH-PISC, Piscataway
Background/Purpose: TREX1 gene encodes the three prime repair exonuclease 1 enzyme that degrades DNA. TREX1 plays a key role in genomic DNA degradation, cell death…
Abstract Number: 0173 • ACR Convergence 2024
Systemic Lupus Erythematosus Mortality—United States, 2018–2022
Danielle Dawson¹, Kurt Greenlund² and Kamil Barbour², ¹CDC, Atlanta, GA, ²CDC, Alpharetta, GA
Background/Purpose: Mortality due to cardiovascular disease, infections, and renal disease is elevated in people with systemic lupus erythematosus (SLE) compared with the general population, but…
Abstract Number: 0197 • ACR Convergence 2024
Characterizing Diet and Neighborhood Resources in Patients with Systemic Lupus Erythematosus
Justin Arnold¹, Dominique Kinnett-Hopkins², Linda Van Horn¹, Grace Whiteford¹, Lutfiyya Muhammad³, Jing Song⁴, Joan Chmiel¹, Anh Chung⁵, Daniel Erickson¹, Holly Milaeger¹, Christie Bartels⁶, Linda Ehrlich-Jones⁷ and rosalind Ramsey-Goldman¹, ¹Northwestern University, Chicago, IL, ²University of Michigan, Ann Arbor, MI, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Northwestern University, Worthington, MN, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Shirley Ryan Ability Lab, Chicago, IL
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory, autoimmune disease that can present with pervasive self-reported fatigue, which negatively impacts the lives of most…
Abstract Number: 0375 • ACR Convergence 2024
Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics
Jasvinder Singh¹, Larry Hearld², Walter Chatham³, Sonali Narain⁴, Narender Annapureddy⁵, Diane Kamen⁶, Kimberly Trotter⁷, vikas Majithia⁸, Zineb Aouhab⁹, Swamy Venuturupalli¹⁰, Daniel Wallace¹¹, rosalind Ramsey-Goldman¹², Alfred Kim¹³, Maureen McMahon¹⁴, S. Sam Lim¹⁵, Kalpana Bhairavarasu¹⁶, Alexa Meara¹⁷, Kenneth Kalunian¹⁸ and Cathy Lee Ching¹⁹, ¹Baylor College of Medicine, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV, ⁴Northwell Health, Great Neck, NY, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Chicago, Chicago, IL, ⁸University of Missisippi Medical Center (UMC), Jackson, MS, ⁹Loyola University Medical Center, Oak Brook, IL, ¹⁰Attune Health, Beverly Hills, CA, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²Northwestern University, Chicago, IL, ¹³Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁵Emory University, Atlanta, GA, ¹⁶Baylor College of Medicine, Sugar Land, TX, ¹⁷The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹⁸University of California San Diego, La Jolla, CA, ¹⁹UMMC, Jackson, MS
Background/Purpose: To implement a self-administered patient decision-aid (PtDA) for lupus in outpatient clinics, assess its reach/penetration within each clinic, and examine patient outcomesMethods: An effective…
Abstract Number: 0607 • ACR Convergence 2024
Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Andrea Fava¹, Michelle Petri², David Jayne³, Patrick G Gavin⁴, Eszter Csomor⁵, Philip Z Brohawn⁴, Daniel Muthas⁶, Adam Platt⁵, Catharina Lindholm⁷ and Nicola Ferrari⁵, ¹Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³University of Cambridge, Cambridge, United Kingdom, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: An elevated type I interferon gene signature (IFNGS) is associated with more active disease in patients with LN.1 Anifrolumab, a type I interferon receptor…
Abstract Number: 0623 • ACR Convergence 2024
Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus
Melissa Munroe¹, Daniele DeFreese², Adrian Holloway², Mohan Purushothaman², Wade DeJager³, Susan Macwana³, Joel Guthridge⁴, Stan Kamp³, Nancy Redinger³, Teresa Aberle⁴, Eliza Chakravarty⁴, Cristina Arriens⁴, Yanfeng Li⁵, hu Zeng⁵, Uma Thanarajasingam⁵, Judith James⁴ and Eldon Jupe², ¹Oklahoma Medical Research Foundation; Progentec Diagnostics, Inc., Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Mayo Clinic, Rochester
Background/Purpose: We have recently validated a plasma Lupus Flare Risk Index (L-FRI; Munroe et al. Ann Rheum Dis. 2024. 83 [Supp 1]: 402) and Lupus…
Abstract Number: 0644 • ACR Convergence 2024
Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set
Wils Nielsen¹, Fadi Kharouf², Carolina Munoz-Grajales³, Aarabi Thayaparan⁴, Melanie Anderson⁵, Lee Simon⁶, Maya Desai⁷, Ioannis Parodis⁸, Alfred Kim⁹, Yvonne Enman¹⁰, Kathleen Bingham¹¹, Dennisse Bonilla¹¹, Julian Thumboo¹², Marta Mosca¹³, Martin Aringer¹⁴, Eric Morand¹⁵, Ian Bruce¹⁶, Vibeke Strand¹⁷ and Zahi Touma⁴, ¹University of Toronto, Markham, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³UHN/TWH, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁶SDG LLC, West Newton, MA, ⁷Ontario College of Art and Design University, Toronto, ON, Canada, ⁸Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁰Karolinska Institutet, Stockholm, Sweden, ¹¹University Health Network, Toronto, ON, Canada, ¹²Singapore General Hospital, Singapore, Singapore, ¹³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ¹⁴University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ¹⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ¹⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁷Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Systemic Lupus Erythematosus (SLE) Working Group was re-established in 2018 to update the SLE Core Outcome Set (COS)…
Abstract Number: 0662 • ACR Convergence 2024
Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
Eric Morand¹, Cristina Arriens², Laura Geraldino³, Ann E. Clarke⁴, Samantha Pomponi⁵, Coburn Hobar⁵, Thomas Wegman⁶, Ravi Koti⁵, Subhashis Banerjee⁵ and Ronald Van Vollenhoven⁷, ¹School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ²Department of Arthritis and Clinical Immunology, Rheumatology, Oklahoma Medical Research Foundation and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Bristol Myers Squibb, Princeton, NJ, ⁶Bristol Myers Squibb, Beaver Falls, PA, ⁷Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase (TYK2) inhibitor approved in multiple countries for the treatment of adults with moderate to severe…
Abstract Number: 0812 • ACR Convergence 2024
A Human Gut Pathobiont Drives Platelet Activation with Microparticle Release and NETosis During Lupus Nephritis Flares
Abhimanyu Amarnani¹, Cristobal Rivera-Martinez¹, Marc Scherlinger², Doua Azzouz¹, Andy Lee¹, Kate Trujillo¹, MacIntosh Cornwell¹, Tyler Weinstein¹, Tatiana Borja³, Bharati Matta⁴, Sharon Chung⁵, Laura Cooney⁶, Uzair Chaudhary¹, Steven Medvedovsky¹, Peter Izmirly¹, Jill Buyon¹, Patrick Blanco⁷, Betsy Barnes⁸, Bhama Ramkhelawon¹, Kelly Ruggles⁹ and Gregg Silverman¹, ¹New York University Grossman School of Medicine, New York, NY, ²Strasbourg University Hospital, Strasbourg, France, ³Feinstein Institutes for Medical Research, New York, NY, ⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ⁵University of California, San Francisco and Immune Tolerance Network, San Francsico, ⁶University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ⁷UMR_CNRS 5164 Immunoconcept, BORDEAUX CEDEX, France, ⁸Feinstein Institutes for Medical Science, Manhasset, NY, ⁹NYU Grossman School of Medicine, Brooklyn, NY
Background/Purpose: SLE is a leading cause of premature death, often from severe complications including lupus nephritis (LN), especially in disadvantaged groups. Despite advances in treatment,…
Abstract Number: 0910 • ACR Convergence 2024
Reduced Adenosine-Mediated Regulatory Activity Exacerbated by an NT5E Loss of Function Mutation Is Linked to Tissue Inflammation and Hypertension in Systemic Lupus Erythematosus
Katherine Owen¹, Isaac Peabody², Mikhail Olferiev³, Tyson Dawson², Prathyusha Bachali⁴, Peter Kasson⁵, Amrie Grammer⁶, Mary Crow³ and Peter Lipsky², ¹RILITE, Charlottesville, VA, ²Ampel Biosolutions, Charlottesville, VA, ³Hospital for Special Surgery, New York, NY, ⁴AMPEL BioSolutions, Redmond, WA, ⁵University of Virginia, Charlottesville, VA, ⁶AMPEL LLC, Charlottesville, VA
Background/Purpose: Adenosine is a purine nucleoside generated by the enzymatic activity of CD73/NT5E, that functions as an endogenous regulator of the immune system critical for…
Abstract Number: 1068 • ACR Convergence 2024
Improving Health Numeracy Literacy in Pediatric Patients with SLE
Nicole Salach¹, Sarah Rogal¹, Jessica Simpson¹, Sangeeta Sule², Abigail Bosk³ and Catherine Park¹, ¹Children's National Hospital, Washington DC, DC, ²Children's National Hospital, Washington, DC, ³Children's National Hospital, Bethesda, DC
Background/Purpose: Health literacy is key to better patient outcomes. One aspect of health literacy that warrants additional investigation in patients who have systemic lupus erythematosus…
Abstract Number: 1273 • ACR Convergence 2024
An Investigation of Traumatic Events and Mental Health in cSLE
Paris Moaf¹, Ashley Danguecan², Michelle Quilter³, Julie Couture⁴, Daniela Dominguez⁵, Lawrence Ng⁶, Asha Jeyanathan⁷, Reva Schachter⁸, Daphne Korczak⁹, Deborah Levy⁶, Linda Hiraki⁶ and Andrea Knight¹⁰, ¹The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Department of Psychology, University of Toronto, Toronto, ON, Canada, ³Whyteman’s Brae Hospital, Kirkcaldy, United Kingdom, ⁴Centre mère-enfant Soleil du CHU de Québec, Québec, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Neurosciences and Mental Health, Research Institute, Toronto, ON, Canada, ⁸Sickkids Toronto, Toronto, ON, Canada, ⁹Hospital for Sick Children, University of toronto, Toronto, ON, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with substantial morbidity, particularly in childhood-onset SLE (cSLE). Mental health conditions such as depression and…
Abstract Number: 1488 • ACR Convergence 2024
Clinical Utility and Performance of Anti-C1q Antibodies for Systemic Lupus Erythematosus: Comparative Analysis of Three Different Assays
Mariana Gonzalez-Trevino¹, MeLea Hetrick¹, Alain Sanchez-Rodriguez², Ali Duarte-Garcia¹ and Anne Tebo³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, ³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
Background/Purpose: SLE is an autoimmune disorder characterized by autoantibody-mediated tissue damage. Antibodies against C1q (anti-C1q) can identify patients with LN and rising titers predict renal…
Abstract Number: 1505 • ACR Convergence 2024
Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters
Sara Ferrigno¹, Elizabeth Arkema², Lina Marcela Diaz-Gallo³, Iva Gunnarsson⁴, Agneta Zickert⁴ and Elisabet Svenungsson⁵, ¹Department of Systems' Medicine, University of Rome Tor Vergata, Rome, Italy, ²Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Sweden, ³Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) patients have higher cardiovascular (CV) risk compared to the general population, with a standardized CV mortality rate of 2-3 and…
Abstract Number: 1521 • ACR Convergence 2024
Contemporary Lupus Nephritis Treatment and Outcomes Among Patients with Systemic Lupus Erythematosus in the United States
Aakash Patel¹, Baijun Zhou², Hyon K. Choi³ and April Jorge¹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Lupus nephritis (LN) is associated with excess morbidity and mortality, with prior studies finding a disproportionate impact on Black patients. We sought to determine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].